Research
Hormonal
Tirzepatide is the first dual receptor agonist incorporated into therapeutic recommendations for type 2 diabetes.
Tirzepatide should be considered as a treatment option for type 2 diabetes.
StrongSupportsmedium confidence
It describes the pharmacology of the first dual receptor agonist, tirzepatide, already incorporated in therapeutic recommendations.
Why this rating
The claim is based on clinical trials mentioned in the abstract.
Source
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Gábor Winkler et al. · Orvosi Hetilap · 2023
DOI 10.1556/650.2023.32710
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →